Hypoglycemic Effect of Insulin-like Growth Factor-1 in Mice Lacking Insulin Receptors

Giovanni Di Cola, Martha H. Cool, and Domenico Accili
Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892

Abstract

We have investigated the metabolic actions of recombinant human IGF-1 in mice genetically deficient of insulin receptors (IR−/−). After intraperitoneal administration, IGF-1 caused a prompt and sustained decrease of plasma glucose levels in IR−/− mice. Plasma free fatty acid concentrations were unaffected. Interestingly, the effects of IGF-1 were identical in normal mice (IR+/+) and in IR−/− mice. Despite decreased glucose levels, IR−/− mice treated with IGF-1 died within 2–3 d of birth, like sham-treated IR−/− controls. In skeletal muscle, IGF-1 treatment caused phosphorylation of IGF-1 receptors and increased the levels of the phosphatidylinositol-3-kinase p85 subunit detected in antiphosphotyrosine immunoprecipitates, consistent with the possibility that IGF-1 stimulates glucose uptake in a phosphatidylinositol-3-kinase–dependent manner. IGF-1 receptor phosphorylation and coimmunoprecipitation of phosphatidylinositol-3-kinase by antiphosphotyrosine antibodies was also observed in liver, and was associated with a decrease in mRNA levels of the key gluconeogenic enzyme phosphoenolpyruvate carboxykinase. Thus, the effect of IGF-1 on plasma glucose levels may be accounted for by increased peripheral glucose use and by inhibition of hepatic gluconeogenesis. These data indicate that IGF-1 can mimic insulin’s effects on glucose metabolism by acting through its own receptor. The failure of IGF-1 to rescue the lethal phenotype due to lack of insulin receptors suggests that IGF-1 receptors cannot effectively mediate all the metabolic actions of insulin receptors. (J. Clin. Invest. 1997. 99:2538–2544.) Key words: diabetes mellitus • ketoacidosis • mutagenesis • genetics • insulin resistance

Introduction

Type I insulin-like growth factor (IGF-1) promotes growth and differentiation in a variety of tissues (1). These effects are largely mediated by the IGF-1 receptor, although IGF-1 can bind with low affinity to the insulin receptor (2). In addition to these effects, IGF-1 can mimic the metabolic actions of insulin to stimulate glucose and amino acid uptake, inhibit gluconeogenesis, and promote lipogenesis. Because of its metabolic effects, IGF-1 has been used in clinical trials of non–insulin-depen-
mice and control littersmates. At birth, pups (∼1 g body wt) were injected with 0.1 ml saline solution containing 0.05 mg/ml recombinant human IGF-1 (rhIGF-1; a kind gift of Genentech Inc., South San Francisco, CA), or with saline alone. Thereafter, mice were either killed within 30 min of injection or were returned to the cage, and the administration of IGF-1 was repeated after 12 h. In some experiments, animals were not killed in order to investigate whether IGF-1 treatment would prolong their life span. However, IR−/− mice invariably died on day 2 or 3. Animals were killed by decapitation, exanguinated, and various organs were quickly removed and snap-frozen in liquid nitrogen for protein, RNA, and DNA isolation. Up to 20 μl of blood were obtained from IR−/+ mice, and 5–10 μl from IR−/− mice. Plasma glucose levels were measured by a glucose oxidase assay, and insulin levels were measured by radioimmunoassay. FFA levels were determined by an enzymatic assay (Wako Bioproducts, Richmond, VA).

**PCR genotyping.** To determine the genotype of newborn mice, DNA was prepared as described (21) and subjected to PCR amplification with two sets of primers, one to detect the wild-type allele, and one to detect the mutant allele. The primers to detect the wild-type allele are derived from the sequence of exon 4 of the mouse insulin receptor gene: upstream primer: 5′ CTG GAT GTG CAC CCC ATG TCT 3′; downstream primer: 5′ TCG GAT GTT GAT GAT CAG GCT 3′. The primers to detect the mutant allele are derived from the sequence of the neomycin phosphotransferase gene; upstream primer: 5′ GAT CGG CCA TTG AAC AAG ATG 3′; downstream primer: 5′ CGC CAA GCT CTT CAG CAA TAT 3′. The size of the expected product is 120 bp for the wild-type and 700 bp for the mutant allele. Standard PCR conditions were employed: initial denaturation of 5 min at 95°C, followed by 30 cycles with annealing at 55°C, extension at 72°C, and denaturation at 94°C, all for 1 min (21).

**Immunoprecipitation and immunoblotting.** Extracts of liver and hind limb muscle were prepared by solubilizing tissues in a buffer containing 1% Triton X-100, 50 mM Hepes, pH 7.6, 150 mM NaCl, 1 mM Na-pyrophosphate, 0.1 M NaF, 10 mM Na-orthovanadate, 4 mM EDTA, and protease inhibitors. After centrifugation to clarify the insoluble material, extracts were adjusted to a concentration of 0.5 mg/ml and subjected to immunoprecipitation with the anti–IGF-1 receptor antibody AB-1 (Oncogene Science Inc., Manhasset, NY) or with the monoclonal antiphosphotyrosine antibody 4G10 (Upstate Biotechnology Inc., Lake Placid, NY). Immunocomplexes were collected by centrifugation after the addition of 40 μl of protein A-Sepharose slurry, washed three times in 0.1% Triton X-100 buffer, and analyzed by SDS-PAGE as previously described (21). Immunoblotting was performed as described with antiphosphotyrosine (Upstate Biotechnology Inc.), anti–PI-3-kinase p85 subunit (Upstate Biotechnology Inc.), and anti–IGF-1 receptor antibodies, followed by detection with a horseradish peroxidase–conjugated goat anti–rabbit or anti–mouse IgG. Densitometric scanning was performed to quantitate the intensity of the bands.

**Purification of IGF-1 receptors.** Confluent monolayers of SV40-transformed hepatocytes (25) derived from either IR−/+ or IR−/− mice were solubilized in Triton X-100 buffer as described above, and the glycoprotein fraction was purified by batch affinity chromatography with wheat germ agglutinin–agarose (EY Laboratories Inc., San Mateo, CA). After elution with 0.3 M n-acetylglucosamine, the protein concentration was adjusted to 0.15 mg/ml, and the extract was phosphorylated in the presence of 1 nM rhIGF-1 and 1053P-ATP as described in previous publications (21). Phosphoproteins were analyzed by immunoprecipitation with anti–IGF-1 receptor antibody (Oncogene Science Inc.) followed by SDS-PAGE and autoradiography.

**Northern blotting analysis.** Total cellular RNA was isolated using a guanidinium isothiocyanate/acid phenol extraction procedure (21). Polyadenylated RNA was further purified by affinity chromatography over an oligo-d(T) column. Northern blotting was performed according to standard techniques using 32P-labeled probes encoding the rat PEPCK (26), the mouse IGF-1 receptor (27), or the rat IGFBP-1 (28).

**Results**

To determine the effects of IGF-1 in mice lacking insulin receptors, newborn mice were treated with rhIGF-1 at a dose of 5 mg/kg or with saline by intraperitoneal injection. The high dose of IGF-1 was chosen to saturate IGF-1 binding to circulating IGF binding proteins. Insulin is known to inhibit expression of IGFBP-1 (29, 30). Therefore, since insulin action is inhibited in IR−/− mice by the absence of insulin receptors, we expected IGFBP-1 levels to be elevated in IR−/− mice. To test this hypothesis, Northern blot analysis was performed on RNA extracted from livers of newborn IR−/+ and IR−/− mice (Fig. 1). When the blots were probed with a 32P-labeled rat IGFBP-1 cDNA, a 2.5-fold increase in IGFBP-1 levels was detected in newborn IR−/− mice. Thus, the lack of insulin action in IR−/− mice causes an increase in IGFBP-1 levels.

A single dose of rhIGF-1 caused a 50% decrease of plasma glucose levels in IR−/+ mice, a 30% decrease in mice heterozygous for the insulin receptor mutation (IR−/+), and a 60% decrease in IR−/− mice (Fig. 2). The decrease was apparent within 1–2 min of the IGF-1 injection and persisted for at least 2 h (data not shown). Similar results were obtained with daily IGF-1 injections for 2 d (data not shown). At least 15 animals of each genotype were assayed for each treatment group. Thus, IGF-1 has both an acute and a chronic effect to decrease plasma glucose levels in IR−/− mice.

To investigate whether the hypoglycemic effect of IGF-1 would rescue the lethal phenotype of IR−/− mice, animals were injected within a few hours (<6) of birth, before the onset of overt ketoacidosis, and treatment was repeated every 12 h thereafter. Invariably, IR−/− mice died of ketoacidosis between days 2 and 3 of treatment, suggesting that administration of IGF-1 cannot rescue the metabolic abnormalities caused by lack of insulin receptors.

We also investigated the effect of IGF-1 treatment on...
PI-3-kinase with IRS molecules. A direct assessment of peptide catalyzing the association of the regulatory (p85) subunit of PI-3-kinase with IRS molecules. A direct assessment of peptide catalyzing the association of the regulatory (p85) subunit of PI-3-kinase with IRS molecules. A direct assessment of peptide catalyzing the association of the regulatory (p85) subunit of PI-3-kinase detected in antiphosphotyrosine immunoprecipitates is bound to IRS-1 (32, 35, 36), the phosphorylation of IGF-1 receptors catalyzing the association of the regulatory (p85) subunit of PI-3-kinase with IRS molecules. A direct assessment of peripheral glucose uptake was not possible due to the small size of the animals (~1 g body wt).

Phosphorylation of IGF-1 receptors was determined in muscle and liver extracts of IGF-1–treated and control mice (Fig. 3). After IGF-1 treatment, IGF-1 receptors were isolated from detergent extracts by immunoprecipitation with antiphosphotyrosine antibody. The immunoprecipitates were analyzed by immunoblotting with anti–IGF-1 receptor antibody (Fig. 3, top). IGF-1 increased to the same extent tyrosine phosphorylation of the IGF-1 receptor β-subunit in IR+/+ mice (Fig. 3, lanes 1, 2, 5, and 6, top) and in IR−/− mice (Fig. 3, lanes 3, 4, 7, and 8, top). Immunoprecipitation and blotting with anti–IGF-1 receptor antibody showed that an equal amount of receptor was loaded in all lanes (Fig. 3, lanes 1–8, bottom).

An important step in insulin- and IGF-1–stimulated glucose uptake is the activation of PI-3-kinase through its interaction with phosphorylated YXXM motifs in IRS-1 and -2 (20, 31–34). Since the majority of PI-3-kinase found in antiphosphotyrosine immunoprecipitates is bound to IRS-1 (32, 35, 36), we set out to determine whether IGF-1 increased the amount of the p85 subunit of PI-3-kinase detected in antiphosphotyrosine immunoprecipitates from muscles and livers of control and treated IR+/+ and IR−/− mice. Phosphotyrosine-containing proteins were isolated by immunoprecipitation with antiphosphotyrosine antibodies. After transferring the immunoprecipitates to a nitrocellulose filter, the amount of PI-3-kinase was estimated by immunoblotting with an antibody against p85. A direct assessment of PI-3-kinase activity was not possible, due to the small amount of material recovered from each mouse. In skeletal muscle of IR+/+ mice, IGF-1 treatment caused a 2.4-fold increase in the amount of PI-3-kinase detected by immunoblotting of antiphosphotyrosine immunoprecipitates with an anti–p85 antibody. In IR−/− mice, a threefold increase was detected (Fig. 4). In liver, IGF-1 treatment was associated with a 1.4-fold increase of coimmunoprecipitated PI-3-kinase in IR+/+ mice, and with a twofold increase in IR−/− mice (Fig. 4). All experiments were performed on pooled animal organs multiple times with virtually identical results.

Activation of PI-3-kinase in liver is required for insulin’s...
mRNA levels decreased by 30% in the basal values in sham-treated animals. Control and IGF-1–treated animals showed differences in PEPCK gene expression as determined by Northern blotting analysis on polyA+ RNA derived from cell types other than the hepatocyte. To confirm the effect of IGF-1 on PEPCK gene expression, we measured PEPCK mRNA levels in livers of control and IGF-1–treated mice by Northern blotting (Fig. 5). RNA was extracted from livers and PEPCK mRNA levels were determined by hybridization with a 32P-labeled rat PEPCK probe. In untreated mice, PEPCK mRNA levels are increased threefold compared with IGF-1–treated mice (Fig. 5, left). After IGF-1 treatment, PEPCK mRNA levels decreased by 30% in IGF-1–treated mice and by 50% in IGF-1–treated mice, suggesting that the effect of IGF-1 on plasma glucose levels is at least in part mediated by decreased gluconeogenesis (Fig. 5, right).

IGF-1 receptors are expressed at very low levels in liver under physiologic conditions (37, 38). We wanted to determine whether the effect of IGF-1 on PEPCK gene expression could be explained by increased levels of IGF-1 receptors. However, Northern blotting analysis on polyA+ RNA derived from and IGF-1–treated mice indicated that the levels of expression of IGF-1 receptors are similar in the two groups (Fig. 6 A, lanes 4 and 6) and that PEPCK receptor mRNA in liver is about threefold less abundant than in skeletal muscle (Fig. 6 A, lanes 1–3 vs. 4–6; please note that 2 μg of polyA+ RNA were loaded in lanes 1–3, and 3 μg in lanes 4–6). Likewise, immunoprecipitation of tyrosine-phosphorylated IGF-1 receptors from IGF-1–treated mice did not reveal any quantitative difference in the phosphorylation of hepatic IGF-1 receptors (Fig. 3, lanes 5–8). It is possible that IGF-1 receptors identified in whole liver preparations are derived from cell types other than the hepatocyte. To address the question of whether IGF-1 receptors are expressed by murine hepatocytes, we employed hepatocyte cell lines derived from IGF-1–treated mice liver (K. Rother, Y. Imai, and D. Accili, manuscript in preparation). IGF-1 receptors were partially purified from these cells using lectin chromatography, and were phosphorylated in vitro using rhIGF-1 (1 nM) and γ[32P]ATP. Consistent with the results obtained in whole liver extracts, IGF-1–treated and IGF-1–treated hepatocytes express comparable amounts of IGF-1 receptors (Fig. 6 B, lanes 7–10). Thus, the effect of IGF-1 on PEPCK gene expression is not explained by increased levels of IGF-1 receptors in liver, and probably reflects a physiologic response to IGF-1.

**Discussion**

Type I insulin-like growth factor can mimic some of insulin’s effects on fuel metabolism (3). However, it is not clear whether the metabolic effects of IGF-1 are mediated by the IGF-1 receptor or by the insulin receptor. In the present study, we have addressed this question using a model of insulin receptor–deficient mice generated by targeted inactivation of the insulin receptor gene. Because lack of insulin receptors is rapidly lethal after birth, we could only perform these experiments in newborn mice. There are two main limitations to our study: first, metabolic regulation in newborn rodents is different from adult rodents and humans. Second, due to the small size of the animals, a complete analysis of IGF-1 effects at the target cell level was not possible.

The main result of this study is that IGF-1 can lower plasma glucose levels in IGF-1–treated mice, but fails to rescue the lethal phenotype due to the insulin receptor gene mutation. The persistent hyperglycemic state of insulin receptor–deficient mice indicates that the metabolic effects of IGF-1 through the IGF-1 receptor are not sufficient to replace completely the effects of insulin. An alternative explanation is that the metabolic derangement caused by the lack of insulin receptors impairs the response to IGF-1. However, treatment with IGF-1 was begun before the onset of overt ketoacidosis and was unable to prevent it.

Phosphorylation of IGF-1 receptors was readily detected in skeletal muscle and liver of IGF-1–treated mice, and was paralleled by an increased amount of PI-3-kinase in antiphosphotyrosine immunoprecipitates, suggesting that IGF-1 may stimulate glucose uptake in skeletal muscle. This possibility is also consistent with the rapid onset of the hypoglycemic effect of IGF-1, which cannot be accounted for by decreased hepatic glucose output, the onset of which is considerably slower (39). The small size of the animals prevented us from measuring directly glucose uptake and PI-3-kinase activity in different subcellular fractions. Since activation of PI-3-kinase in response to IGF-1 has also been linked to the mitogenic response to IGF-1 (2), a more conclusive interpretation of these data awaits further experiments in cultured cells derived from IGF-1–treated mice.

The hypoglycemic effect of IGF-1 is also associated with decreased gluconeogenesis, which is inappropriately elevated in IGF-1–treated mice. Suppression of PEPCK gene expression in IGF-1–treated mice was as marked as in IGF-1–treated mice. It remains to be determined whether this effect is due to a direct activation of the scarce hepatic IGF-1 receptors (37, 38), or to an indirect effect mediated by inhibition of glucagon secretion (40, 41). Interestingly, this effect is consistent with studies of humans with NIDDM, in whom IGF-1 treatment is quite effective in improving fasting glucose levels, an indicator of hepatic gluconeogenesis (7, 41, 42).

**Figure 5.** Northern blotting analysis of PEPCK gene expression in mouse liver. Total RNA was isolated from livers of control and IGF-1–treated mice, size-fractionated on a denaturing agarose-formaldehyde gel and transferred to nitrocellulose. After hybridization of the filter to a 32P-labeled rat PEPCK probe, the intensity of the bands was quantitated using scanning densitometry. The filters were stripped and reprobed with an actin control to normalize the intensity of the signal to the amount of RNA loaded onto each lane. The autoradiogram on the left side shows the basal levels of PEPCK expression in sham-treated animals (lane 1, IGF-1+/+; lane 2, IGF-1+/−; lane 3, IGF-1−/−). The bar graph on the right side shows a quantitation of the effect of IGF-1 treatment in IGF-1+/+ and IGF-1−/− mice. Livers from three animals were pooled for each determination. Data are presented as a percentage of the basal values in sham-treated animals.
IGF-1 treatment failed to lower FFA levels in IR+/+ and IR-/- mice. The failure of IGF-1 to promote lipogenesis and thus decrease FFA levels is consistent with some data in normal human subjects after chronic IGF-1 administration (43). However, in most human and animal studies, IGF-1 has been shown to decrease FFAs and triglyceride levels (7, 41, 44). It should be emphasized that the effect of IGF-1 in our experimental model may be influenced by the fact that newborn mice are in a physiologic state of ketosis due to their high fat diet (~70% of all caloric intake) (45–47). Elevated levels of circulating triglycerides may explain the persistent ketotic state of the IR-/- mice after IGF-1 treatment.

Several studies have analyzed the effects of IGF-1 in patients with varying degrees of insulin resistance and NIDDM. IGF-1 improves metabolic control in patients with NIDDM by improving insulin sensitivity, reducing glucose levels, and suppressing FFA release from adipocytes. Significant side effects have been reported in some patients (7, 48). Interestingly, data in insulin-resistant humans and rodents show that IGF-1 is more potent in suppressing hepatic glucose production (7, 41, 42) than in stimulating glucose uptake in skeletal muscle (49, 50).

The effects of IGF-1 in patients with genetic syndromes of insulin resistance are less clear. In patients whose insulin resistance is due to mutations of the insulin receptor gene, it appears that higher doses of IGF-1 are required to improve metabolic control (8, 51–56). Thus, it is possible that in these patients the effects of IGF-1 are due to activation of residual insulin receptors or hybrid insulin/IGF-1 receptors. Indeed, most patients with extreme insulin resistance retain some degree of insulin receptor function. Interestingly, IGF-1 failed to improve the metabolic control of a patient homozygous for a null allele of the insulin receptor gene (51), but high doses of IGF-1 (1 mg/kg) improved metabolic control in a patient homozygous for a mutation in the insulin receptor’s kinase domain (57). In summary, it is not clear whether in humans IGF-1 can act as a hypoglycemic agent in the absence of insulin receptors. Thus, there may be significant differences between humans and rodents with respect to the ability of IGF-1 recep-

Figure 6. Analysis of IGF-1 receptor expression in liver. (A) PolyA+ RNA was isolated from skeletal muscles (lanes 1–3) and livers (lanes 4–6) by affinity chromatography over oligo-(d)T cellulose and analyzed by Northern blotting. 2 μg of polyadenylated RNA were loaded in lanes 1–3, and 3 μg in lanes 4–6. Hybridization to a mouse IGF-1 receptor cDNA probe and quantitation were performed as described in Methods. (B) In vitro phosphorylation of lectin-purified IGF-1 receptors isolated from SV40-transformed hepatocytes from IR+/+ and IR-/- mice. Glycoproteins were incubated in the absence or presence of 1nM rhIGF-1 for 1 h at room temperature, phosphorylated with [γ-32P]ATP, and immunoprecipitated with an anti–IGF-1 receptor antibody (see Methods). Autoradiography was employed to detect the phosphorylated β-subunit of the IGF-1 receptor.
tors to mediate fuel metabolism. Our studies indicate that in newborn rodents IGF-1 can lower plasma glucose levels through its own receptor in the absence of insulin receptors. The derivation of permanent cultured cells from IR−/− mice will enable us to address whether IGF-1 receptors mediate this effect directly or through inhibition of counter-regulatory hormones.

Acknowledgments

We thank Dr. Ross Clark (Genentech Inc.) for advice on IGF-1 administration. We are indebted to Genentech Inc. for the generous gift of the rat IGFBP-1 probe. Finally, we thank Dr. Derek LeRoith (National Institutes of Health) for his critical reading of the manuscript.

These studies were partially supported through a research grant from the American Diabetes Association to D. Accili.

References

2544 Di Cola et al.


